• Loss after tax up 30% to $3.19 million
• Cash position of $7.12 million at 31 December 2025
• Commenced Phase IIa clinical trial of lead drug candidate Xolatryp

Nyrada Inc, a clinical-stage biotechnology company focused on the development of innovative small-molecule therapies, has reported its financial results for the half-year ended 31 December 2025. The company recorded a loss after tax of $3,187,188, a 30% increase compared to the previous corresponding period. This was driven by research and development expenditure of $1,659,279 and corporate and administration expenses of $590,650. The company's cash position as at 31 December 2025 was $7,122,199, up from $2,930,601 as at 30 June 2025. Nyrada's key focus during the half-year was the development of its lead drug candidate, Xolatryp (previously called NYR-BI03), a small molecule therapy that inhibits calcium ion influx via TRPC 3/6/7 channels. Xolatryp has shown promise in protecting the heart from ischemia-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after a heart attack. Nyrada announced the successful completion of a Phase I clinical trial for Xolatryp, which demonstrated a strong safety profile and predictable pharmacokinetics. The company has now received approval to commence a Phase IIa clinical trial to assess the safety and preliminary efficacy of Xolatryp in heart attack patients undergoing angioplasty with stenting. Nyrada remains committed to developing treatments for diseases with unmet clinical needs and will also be investigating the potential efficacy of Xolatryp in other indications.

Nyrada will be commencing and advancing its Phase IIa clinical trial to assess safety and preliminary efficacy of Xolatryp in heart attack patients. The company will also be investigating the potential efficacy of Xolatryp in other diseases and other non-intravenous formulations.